Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Erythromycin + benzoyl peroxide** is a fixed-dose topical combination medication for the treatment of mild to moderate acne vulgaris. Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by reversibly binding to the 50S ribosomal subunit, reducing the growth of acne-causing bacteria such as Cutibacterium (Propionibacterium) acnes. Benzoyl peroxide is a bactericidal agent that releases free-radical oxygen species, oxidizing bacterial proteins and reducing the bacterial load on the skin. In addition to its antibacterial effects, benzoyl peroxide has keratolytic and desquamative properties, helping to clear pore blockages. The combination is designed to be more effective and reduce resistance selection compared to erythromycin alone[1][2][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on erythromycin + benzoyl peroxide.